Granules Pharma incorporates wholly owned subsidiary in Canada

In September, Granules India Limited, in partnership with the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, inaugurated the Dr. Chigurupati Centre of Excellence in Innovative and Sustainable Pharmaceutical Development (CCE-ISPD).

Read also: Granules India, NIPER SAS Nagar inaugurate Centre of Excellence for Sustainable Pharma Innovation

Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered in Hyderabad with best-in-class facilities. Amongst the few pharmaceutical companies in the world to be present across the manufacturing of the entire pharmaceutical value chain — from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFls), and Finished Dosages (FDs), Granules products are distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US and UK. The Company has 10 manufacturing facilities out of which 8 are located in India and 2 are in the USA and has regulatory approvals from the US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

Read also: Intas Pharma appoints Umesh Gupta as Associate Executive Vice President - Manufacturing Operations